Compact proton therapy systems for cancer treatment centers
Mevion designs and manufactures proton therapy accelerators for oncology, with a compact gantry-mounted architecture that reduces capital and operating costs relative to traditional systems. The company is mid-stage (51–200 employees) and engineering-heavy, with active hiring across manufacturing and support roles—consistent with scaling production and clinical deployment. Pain-point data shows focus on equipment uptime, clinical adoption barriers, and margin improvement, suggesting the business is moving from product-market fit toward operational efficiency and customer success.
Mevion Medical Systems manufactures proton therapy systems for cancer centers and hospitals. The core product line—the S250 Series—includes three variants: the S250 (volumetric delivery), S250i with HYPERSCAN (intensity-modulated proton therapy), and S250mx (multi-room configurations with redundancy). The company is based in Littleton, Massachusetts, with operations in the United Kingdom, Japan, and a joint venture in China. Mevion's differentiation centers on a proprietary gantry-mounted proton accelerator and direct beam technology designed to lower system complexity and cost while improving beam quality and facility uptime.
Mevion manufactures proton therapy systems for cancer treatment. Founded in 2004 and based in Littleton, MA, the company has 51–200 employees and serves oncology centers globally through direct sales and joint ventures.
Mevion uses C/C++, VxWorks, Qt, and Boost for real-time control systems; CAD tools (AutoCAD, Revit, SolidWorks) for mechanical design; and industrial controls (ControlLogix, SPC) for manufacturing and quality processes.
Other companies in the same industry, closest in size
Mevion Medical Systems's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.